Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/12263

Title: Premature discontinuation during the UPLIFT study
Authors: Decramer, Marc
Molenberghs, Geert
Liu, Dacheng
Celli, Bartolome
Kesten, Steven
Lystig, Theodore
Tashkin, Donald P.
Issue Date: 2011
Citation: RESPIRATORY MEDICINE, 105(10). p. 1523-1530
Abstract: Rationale: Placebo-controlled clinical trials on COPD are characterized by premature discontinuation. At present, no clear insight into this phenomenon is available. Objective: To obtain better insight into the phenomenon of premature discontinuation. Methods: We analyzed the pattern of discontinuation in the UPLIFT-trial. Measurements and main results: Premature discontinuation was substantial and greater in the placebo than in the tiotropium group (45 vs. 37%, p < 0.001). Patients discontinuing were characterized by more severe COPD (p < 0.0001), greater number of pack years (p < 0.002), smaller prebronchodilator and post-bronchodilator FEV(1) (p < 0.0001 for both), and worse SGRQ scores < 0.0001). Rates of decline of FEV(1) and SGRQ were greater in non-completers (p < 0.0001 for both). The latter differences increased over time indicating that the evolution of variables in time was related to trial completion. The risks of exacerbations and hospitalizations were greater in non-completers. In logistic regression analysis BMI, post-bronchodilator FEV(1), male gender and treatment with tiotropium were positively related to trial completion, whereas age, worse SGRQ, female gender, current smoking and assignment to the placebo group were negatively related. Conclusion: Assignment to the control group is related to premature discontinuation. Discontinuation was important and selective in this large trial. Pulmonary function, health-related quality of life and smoking are the most important other variables related to discontinuation. The evolution of variables during the trial is also related to discontinuation. Complete follow-up of discontinued patients may provide better insight into the efficacy of medication in future trials. (C) 2011 Elsevier Ltd. All rights reserved.
Notes: [Decramer, M; Molenberghs, G] Univ Leuven, Univ Hosp, Div Resp, B-3000 Louvain, Belgium [Molenberghs, G] Univ Hasselt, Diepenbeek, Belgium [Celli, B] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA [Liu, DC; Kesten, S; Lystig, T] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA [Tashkin, DP] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
URI: http://hdl.handle.net/1942/12263
DOI: 10.1016/j.rmed.2011.04.002
ISI #: 000294514800014
ISSN: 0954-6111
Category: A1
Type: Journal Contribution
Validation: ecoom, 2012
Appears in Collections: Research publications

Files in This Item:

Description SizeFormat
Published version300.56 kBAdobe PDF

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.